GSK and generic drugmakers prepare for marathon CMA court fight
GlaxoSmithKline sold paroxetine as Seroxat (Credit: Flickr user Jussi Mononen (CC-BY-2.0))
Six companies are set to begin a marathon five-week appeal against the UK Competition and Markets Authority’s first pay-for-delay decision.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below